Director/PDMR Shareholding

RNS Number : 8429K

AstraZeneca PLC

26 September 2016

 

26 September 2016 16:00

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.

One ordinary share equals two ADSs.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sean Bohen
2	Reason for the notification
a)	Position/status	Executive Vice-President, Global Medicines Development and Chief Medical Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	Not applicable
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 046353108
b)	Nature of the transaction	Acquisition of AstraZeneca American Depositary Shares pursuant to the vesting of an award under the AstraZeneca Restricted Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) $33.97 12,385
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	26 September 2016
f)	Place of the transaction	New York

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Media Enquiries
Neil Burrows	UK/Global	[phone]
Vanessa Rhodes	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
UK
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Nick Stone	Respiratory & Autoimmunity	[phone]
Henry Wheeler	Oncology	[phone]
Christer Gruvris	Infection & Neuroscience	[phone]
US
Lindsey Trickett	Cardiovascular & Metabolic Diseases	[phone]
Mitchell Chan	Oncology	[phone]
Toll-free		[phone]

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

 

END

 

 

DSHUNUORNOAKUAR